Edition:
United Kingdom

Thermo Fisher Scientific Inc (TMO.N)

TMO.N on New York Stock Exchange

292.09USD
4:56pm BST
Change (% chg)

$2.27 (+0.78%)
Prev Close
$289.82
Open
$291.00
Day's High
$293.66
Day's Low
$290.15
Volume
74,502
Avg. Vol
376,517
52-wk High
$305.43
52-wk Low
$208.34

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics And Brammer Bio Enter Gene Therapy Collaboration
Monday, 1 Jul 2019 

July 1 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS AND BRAMMER BIO, A PART OF THERMO FISHER SCIENTIFIC, ENTER STRATEGIC GENE THERAPY DEVELOPMENT AND MANUFACTURING COLLABORATION.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING COLLABORATION WITH THERMO FISHER SCIENTIFIC.AMICUS THERAPEUTICS - THERMO FISHER, CO TO DEVELOP PLATFORM MANUFACTURING CAPABILITIES TO SUPPORT BROADER PORTFOLIO OF AAV GENE THERAPY PROGRAMS.  Full Article

Thermo Fisher Scientific Acquires HighChem, Provider Of Mass Spectrometry Software
Thursday, 6 Jun 2019 

June 6 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC ACQUIRES HIGHCHEM, PROVIDER OF MASS SPECTROMETRY SOFTWARE.THERMO FISHER SCIENTIFIC INC - TERMS OF ACQUISITION WERE NOT DISCLOSED..  Full Article

Newomics Announces A Co-Marketing Deal With Thermo Fisher (June 4)
Monday, 3 Jun 2019 

Newomics :NEWOMICS ANNOUNCES A CO-MARKETING AGREEMENT WITH THERMO FISHER SCIENTIFIC.NEWOMICS - TO JOINTLY MARKET MULTINOZZLE EMITTERS FROM NEWOMICS & LIQUID CHROMATOGRAPHY & MASS SPECTROMETRY SYSTEMS FROM THERMO FISHER.  Full Article

Thermo Fisher Scientific Sets Quarterly Cash Dividend Of $0.19 Per Share
Thursday, 23 May 2019 

May 23 (Reuters) - Thermo Fisher Scientific Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.19PER SHARE.  Full Article

UK's CMA Says Thermo Fisher-Roper Deal Raises Competition Concerns
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - UK's CMA::THERMO FISHER'S ACQUISITION OF GATAN FROM ROPER RAISES CONCERNS THAT CUSTOMERS USING SPECIALIST MICROSCOPES COULD FACE HIGHER PRICES.THERMO FISHER ACQUISITION OF GATAN FROM ROPER RAISES CONCERNS THAT CUSTOMERS USING SPECIALIST MICROSCOPES COULD FACE LOWER QUALITY PRODUCTS.HAS CONCERNS THAT DEAL COULD ADVERSELY AFFECT THERMO FISHER TWO RIVALS IN SECTOR, WHO USE GATAN PERIPHERALS WITH THEIR ELECTRON MICROSCOPES.CONCERNED THAT PROPOSED DEAL COULD ALLOW THERMO FISHER TO WEAKEN ITS COMPETITORS.MERGER WILL LEAVE THERMO FISHER WITH INSUFFICIENT COMPETITION IN MARKET FOR DIRECT DETECTION CAMERAS.  Full Article

Achaogen Announces FDA Clearance & Launch Of Thermo Scientific QMS Plazomicin Immunoassay
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES FDA CLEARANCE AND LAUNCH OF THE THERMO SCIENTIFIC QMS PLAZOMICIN IMMUNOASSAY.ACHAOGEN - FDA'S CENTER FOR DEVICES AND RADIOLOGICAL HEALTH HAS PROVIDED CLEARANCE FOR THE THERMO SCIENTIFIC QMS PLAZOMICIN IMMUNOASSAY.ACHAOGEN - THERMO FISHER SCIENTIFIC AND ACHAOGEN JOINTLY DEVELOPED QMS PLAZOMICIN IMMUNOASSAY.  Full Article

Thermo Fisher Scientific Sets Quarterly Cash Dividend Of $0.17 Per Share
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC DECLARES QUARTERLY DIVIDEND.SETS QUARTERLY CASH DIVIDEND OF $0.17PER SHARE.  Full Article

Thermo Fisher Scientific Elects New Director To Board
Wednesday, 7 Nov 2018 

Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC ELECTS NEW DIRECTOR TO BOARD.THERMO FISHER SCIENTIFIC INC - APPOINTMENT BRINGS TOTAL NUMBER OF THERMO FISHER BOARD MEMBERS TO 12.  Full Article

Thermo Fisher Scientific Sets Quarterly Cash Dividend Of $0.17 Per Share
Thursday, 24 May 2018 

May 24 (Reuters) - Thermo Fisher Scientific Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.17PER SHARE.  Full Article

Thermo Fisher Scientific CEO Marc Casper's FY 2017 Total Compenstion Was $22.3 Mln VS $17.8 Mln
Tuesday, 10 Apr 2018 

April 10 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC CEO MARC N. CASPER'S FY 2017 TOTAL COMPENSTION WAS $22.3 MLN VS $17.8 MLN - SEC FILING.  Full Article

Photo

U.S. healthcare stocks shielded from political pressures prove profitable

NEW YORK U.S. healthcare investors have found success this year buying stocks of companies whose products improve eyesight, treat pets and fix crooked teeth, all viewed as unlikely to fall victim to political and regulatory issues pressuring a wide swath of the sector.